Compare Ascendis Pharma A/S (ASND) vs Union Pacific Corporation (UNP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Union Pacific Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Union Pacific Corporation trades at $287.99 (market cap $170.37B). The key difference: Union Pacific Corporation is far larger — about 9.6× Ascendis Pharma A/S's market cap, and Union Pacific Corporation pays a 1.92% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | UNP | |
|---|---|---|
Market Cap | $17.74B | $170.37B |
Sector | Health | Industrials |
52-Week High | $277.18 | $286.96 |
52-Week Low | $163.32 | $214.91 |
Enterprise Value | $18.11B | $200.84B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Union Pacific (UNP) trades at $286.96, up 0.67% today, with strong technical momentum indicated by bullish moving averages. The company maintains robust fundamentals with a 29.2% net income margin and consistent earnings beats in recent quarters. Key developments include the proposed $85 billion merger with Norfolk Southern, though regulatory scrutiny remains. Cash flow from operations remains healthy at $9.29 billion for 2025, supporting dividend payments and strategic initiatives.
Outlook remains positive with analyst consensus targeting $296.27, though risks include merger approval uncertainties and a class-action lawsuit. The stock's current valuation at 23.62 P/E reflects premium pricing, requiring sustained earnings growth to justify further upside. Near-term focus is on Q2 2026 earnings release scheduled for July 23, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
